RELA and ovarian carcinoma: The results revealed that RB was able to reduce p65 phosphorylation in a panel of carcinoma cell lines including Human liver hepatocellular cells HepG2 cells, human myeloid leukemia cell line K562 cells and adriamycin-resistant K562/AO2 cells in indicated dose, whereas slight effect on human ovarian cancer SKOV3 and human lung adenocarcinoma A549 cells (Figure S1).